Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + PD-1 Inhibitor in Recurrent Nasopharyngeal Carcinoma
NCT07781358Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in nasopharyngeal carcinoma (NPC). Started Aug 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07781358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07781358.